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The susceptibility to Fas-mediated apoptosis was evaluated in seven T-cell lines (two infected with HTLV-2, one with
HTLV-1, and four HTLV-free) as well as in Jurkat cells transfected with a Tax-2 expressing vector. Fas-mediated apoptosis was
significantly reduced in the HTLV-1- and HTLV-2-infected lines in comparison with the HTLV-free lines regardless of the
surface expression of Fas antigen (which was no different in the infected and uninfected cells). Fas-mediated apoptosis was
also significantly inhibited in Jurkat cells transfected with the Tax-2 expressing vector without any modification in Fas
expression. There was significantly more antiapoptotic Bcl-xL mRNA and protein in the transfected than in the untransfected
Jurkat T cells. In conclusion, our results suggest that HTLV-2 is capable of inhibiting Fas-mediated apoptosis by means of a
mechanism involving the tax-2 gene and probably the expression of bcl-xL messenger and protein. © 2001 Academic Press
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Human T lymphotropic virus type 2 (HTLV-2) is an
oncoretrovirus that is endemic in some American Indian
populations and widespread among intravenous drug
users (IVDUs) living in the USA and some European
countries (Khabbaz et al., 1992; Zehender et al., 1996).
The pathogenic role of HTLV-2 in any human disease
is still under investigation. It has so far been associated
with sporadic cases of a myelopathy resembling tropical
spastic paraparesis/HTLV-associated myelopathy (TSP/
HAM) (Murphy et al., 1997; Berger et al., 1991a,b), as well
as with peripheral nerve disorders (Beilke et al., 1994;
Dooneief et al., 1996) including a considerable percent-
age of cases of predominantly sensory polyneuropathy
(PSP) occurring in the late stages of HIV-1 infection
(Zehender et al., 1995). Moreover, HTLV-2 is capable of
transforming cells in vitro and causing spontaneous lym-
phocyte proliferation (Tarsis et al., 1998; Wiktor et al.,
1991). HTLV-2 has cell tropism for T cells, in particular
CD8-positive cells. We have recently shown that HTLV-2
infects cells of the monocyte/macrophage lineage in
patients with PSP and B lymphocytes (Zehender et al.,
1998). The mechanisms by which HTLV-2 may damage
the nervous system and induce cell transformation are
still obscure. Recent data have shown that human T-
lymphotropic virus type 1 (HTLV-1) interferes with Fas-
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ie Infettive e Tropicali, Universita` di Milano - c/o Ospedale L. Sacco,
ia G. B. Grassi, 74-20157 Milano, Italy. Fax: 139-02-3566644. E-mail:
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43mediated apoptosis. It has been suggested that a mod-
ification of the apoptotic pathway may be a pathogenic
mechanism in HTLV-1-related lymphoproliferative, neu-
rological and autoimmune diseases in humans (Arai et
al., 1998; Copeland et al., 1994; Debatin et al., 1990; Guyot
et al., 1996) and animal models (Kishi et al., 1997).
The aim of this study was to investigate the influence
of HTLV-2 infection on Fas-mediated apoptosis by anal-
ysing the susceptibility to apoptosis of human T-cell lines
derived from HTLV-2-infected individuals and HTLV-2-
negative cells transfected with a Tax-2 expressing vector.
Finally, we compared the expression of pro- and anti-
apoptotic proteins of the Bcl-2 family in Tax-2 transfected
or untransfected T cells.
RESULTS
T-cell line characterization and susceptibility to Fas-
mediated apoptosis
Susceptibility to Fas-mediated apoptosis was investi-
gated in two HTLV-2-infected cell lines (MoT and C19),
one HTLV-1-infected cell line (MT2), and four HTLV-free
(Jurkat, CEM, Molt and H9) cell lines.
Phenotype characterization showed that all of the an-
alyzed T-cell lines were CD4 and Fas antigen positive
and CD8 negative. The percentage of Fas-expressing
cells ranged from 51.4 to 97.0%, without any significant
difference among the lines (Table 1).
The presence of HTLV-1 proviral sequences in the
MT2 and HTLV-2 proviral sequences in MoT and C19
was confirmed by PCR (data not shown). All of the other
0042-6822/01 $35.00
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44 ZEHENDER ET AL.T-cell lines were negative for viral DNA or RNA se-
quences.
A high frequency of apoptosis (ranging from a mean of
67.5 6 6.3% to a mean of 96.6 6 1.2% by TUNEL assay)
as induced in all of the HTLV-free T-cell lines after
ulturing in the presence of the anti-Fas monoclonal
ntibody. On the contrary, the HTLV-2-infected MoT and
19 cells showed a significantly lower level of apoptosis
fter anti-Fas treatment (mean values of 3.2 6 2.7 and
5.3 6 10% by TUNEL assay: P , 0.001 comparing the
ean values of HTLV-free and HTLV-2-positive cells),
imilar to that of the HTLV-1-infected MT2 (17 6 18.3% by
TUNEL assay) (Fig. 1). The same results were obtained
when the percentage of apoptotic cells was evaluated by
fluorescence microscopy after Hoechst 33372 staining
(Table 2). Further TUNEL and Hoechst staining experi-
ments gave similar results, and so only the TUNEL assay
data are reported below.
No correlation was observed between the percentage
of Fas-expressing cells and the percentage of apoptosis
(correlation coefficient: 0.4; P 5 0.3 at Spearman’s test).
TABLE 1






HTLV-2 positive MOT 98.8 51.4
C19 98.0 75.5
TLV-1 positive MT2 93.0 75.8




FIG. 1. Mean percent of anti-Fas antibody-induced apoptosis (error b
represent untreated cell cultures. The percentage of apoptosis in HTLV-2-infe
that observed in HTLV-free cell lines but comparable with that observed in thTreatment of HTLV-free T cells with HTLV-2-positive
supernatant
No significant difference was observed in the suscep-
tibility to Fas-mediated apoptosis of the Jurkat cells
treated with the MoT supernatants (56.1 6 8.7% using
heat-inactivated and 59.1 6 11.8% using crude superna-
tant) and those treated with the H9 supernatant (69.5 6
12.2%; P 5 0.2).
Fas-mediated apoptosis in Jurkat cells transfected
with a Tax-2 expressing vector
To investigate the possible role of HTLV-2 Tax protein
in inhibiting Fas-induced apoptosis, we studied a T-cell
line (Jurkat) transfected with a Tax-2 expressing vector.
Limiting dilution (LD) RT–PCR revealed a mean titer of
4.7 PU/103 cells of tax2/rex2 RNA after transfection. The
w standard deviations) in different T-cell lines (white bars). Black bars
TABLE 2
Percentages of Apoptotic Cells Evaluated by Means of Hoechst












H9 15.3 81.2 11.2 96.2
JURKAT 20.4 76.1 11.1 96.3
CEM 6.7 96.6 2.4 82.2
MOLT 9.4 75.8 4.0 72.0
MT2 2.4 4.0 0.4 4.5
MOT 1.3 1.3 2.0 5.2
C19 2.0 4.4 3.8 8.0ars sho
cted cell lines (C19 and MoT) is significantly lower (P , 0.001) than









45FAS-MEDIATED APOPTOSIS IN HTLV-2 INFECTED T-CELL LINESentity of tax2/rex2 expression was compared with that of
highly expressed ubiquitous mRNA coding for beta-
ctin in the same cells. A mean ratio of 0.7 was found
etween the tax2/rex2 and beta-actin titers. The percent-
age of apoptotic cells after anti-Fas treatment was mea-
sured in the transfected and untransfected Jurkat cells,
as well as in a cell line transfected with empty vector. As
shown in Table 3, in comparison with untransfected
cells, a significant (P 5 0.002) reduction in Fas-apopto-
sis was found in the cells transfected with the Tax-2
expressing vector but not in those transfected with the
empty vector. No modification in surface Fas expression
was observed after transfection (98.2%).
Expression of bcl-2, bcl-x, and bax genes
The HTLV-2-infected MoT cells showed high levels of
bcl-2, bcl-xL, and bax mRNAs (1.75 6 0.2, 1.75 6 0.1, and
1.3 6 0.7 PU/103 cells); the expression of bcl-xS mRNA
was lower (0.18 6 0.007 PU/103 cells).
The transfected Jurkat cells showed significant bcl-xL
overexpression in comparison with the untransfected
Jurkat cells (0.6 6 0.3 vs 0.075 6 0.09 PU/103 cells; P 5
0.03), but there was no significant difference in bcl-2
TABLE 3
Fas-Mediated Apoptosis in Jurkat Cells Transfected
or Not With Tax-2 Expressing Vector
Fas apoptosis
ells transfected with Tax-2 expressing vector 27.1 6 10.0*
ntransfected cells 56.9 6 13.8*
ells transfected with empty vector 60.2 6 11.1
Note: Mean percent of apoptotic cells 6 SD.
* P 5 0.002.
3FIG. 2. Titers (PU/10 cells) of the bcl-2, bcl-xL, bcl-xS, and bax mRNA in un
bcl-xL transcripts were significantly more expressed in the transfected than i(0.75 6 0.63 vs 0.25 6 0.13 PU/103 cells; P 5 0.3), bcl-xS
(0.25 6 0.12 vs 0.08 6 0.06 PU/103 cells; P 5 0.1), or bax
messenger levels (0.43 6 0.32 vs 0.9 6 0.3 PU/103 cells;
P 5 0.6) (Fig. 2).
Interestingly, the ratio between the long and short
bcl-x transcripts was, respectively, 1:1 and 3:1 in the
untransfected and transfected Jurkat cells and 10:1 in the
MoT cells.
Moreover, there was a marked inversion of the ratio
between the bax and bcl-xL mRNA titers in the cells after
ransfection (12 before and 0.7 after transfection); a bax:
cl-xL ratio of 0.7 was observed also in Mot cells. West-
ern blot analysis showed a higher concentration of Bcl-xL
in the transfected than in the untransfected Jurkat cells
(densitometric analysis revealed up to 3.5 times greater
reactivity in the former; P 5 0.002) (Fig. 3a,b). On the
contrary, no difference was found in the expression of
Bcl-2 or Bax proteins in the same cells by either Western
blot or cytofluorimetric analysis (data not shown).
DISCUSSION
The apoptosis mediated by the Fas antigen plays a
key role in the regulation of tissue turnover and the
peripheral surveillance of immune tolerance (Nagata and
Golstein, 1995). Among its other functions, the Fas anti-
gen participates in host defence against microorgan-
isms, and virus-infected cells can be eliminated by Fas-
mediated apoptosis triggered by T-lymphocytes or NK
cells. For this reason, a number of viruses (including
herpesviruses, adenoviruses, and poxviruses) have de-
veloped still largely unexplored mechanisms that inter-
fere with host cell apoptosis as a survival strategy (Meinl
et al., 1998). It is well known that the HTLV-1 and HIV-1
human retroviruses can affect the apoptotic pathway of
infected cells (Meinl et al., 1998), but conflicting resultstransfected (striped bar) and transfected (dotted bar) Jurkat cells. The


































































46 ZEHENDER ET AL.have been reported concerning the effects of HTLV-1
infection on Fas-mediated apoptosis (Debatin et al.,
1990; Arai et al., 1998; Copeland et al., 1994; Chen et al.,
997). The observed discrepancies have been explained,
uggesting that cell lines actively expressing HTLV-1
roteins are resistant, whereas infected cells not ex-
ressing HTLV-1 proteins (such as the majority of the
ells derived from ATL patients) are susceptible to Fas-
ediated apoptosis (Arai et al., 1998; Copeland et al.,
994). The inhibition of the apoptotic mechanism in
TLV-1-infected T-lymphocytes may play an important
ole in the pathogenesis of virus related lymphoprolifera-
ive diseases. Moreover, recent results have also shown
ncreased resistance to Fas apoptosis in T cells derived
rom patients with TSP/HAM (Arai et al., 1998) and from
ransgenic mice carrying the env-pX region of HTLV-1
which are highly susceptible to autoimmune arthropa-
hy, a condition that is associated with HTLV-1 infection)
Kishi et al., 1997; Nishioka et al., 1996).
In this study, we found that human T-cell lines infected
with HTLV-2 were resistant to Fas-mediated apoptosis to
a similar or greater extent than the T-cell line infected
with HTLV-1. The resistance was not due to the down-
regulation of Fas receptor. This result suggests that
HTLV-2 can interfere with Fas-pathway in infected T-
lymphocytes.
The in vitro infection of Jurkat cells with HTLVs is
enerally not very efficient (Hoffman et al., 1992; Kuroda
t al., 1992). In our experience, Jurkat cells exposed to
he crude cell-free supernatant of MoT cells give only a
FIG. 3. (a) Western blot analysis of Bcl-xL expression in Jurkat cells
lane 2), Jurkat cells transfected with a Tax-2 expressing vector (lanes
–5), and MoT cells (lane 6). Lane 1: molecular weight marker (30 kDa).
b) Densitometric analysis of Bcl-xL protein expression in untransfected
and transfected Jurkat cells. The results are expressed as mean per-
centages of uninfected cells.mall number of provirus-carrying cells (always ,3%—
ata not shown), and this may explain why we did not
p
tbserve any modification in the susceptibility of these
ells to Fas-mediated apoptosis.
It has been reported that the inactivated supernatants
f some HTLV-1-positive T-cell lines can transfer resis-
ance to apoptosis to uninfected cells (Copeland et al.,
994). The absence of any significant reduction in Fas-
ediated apoptosis in Jurkat cells after treatment with
he crude or heat-inactivated MoT supernatant suggests
hat mere contact with virus particles or viral products is
ot sufficient to confer protection in the case of HTLV-2.
On the contrary, the Jurkat cells did develop resistance
o Fas-mediated apoptosis after transfection with a Tax-2
xpressing vector. Also in this case, the resistance to
poptosis was not due to the downregulation of surface
as antigen. Our findings therefore suggest that, like its
TLV-1 counterpart, Tax-2 plays an important role in
nducing resistance to Fas-mediated apoptosis in in-
ected T-lymphocytes. Recent studies have shown that
TLV-2 is involved in the pathogenesis of some neuro-
ogic disorders resembling HTLV-1-associated TSP/HAM
Murphy et al., 1997). Moreover, a possible role of HTLV-2
n T-cell lymphomas has also been recently suggested
Poiesz et al., 2000). The resistance to apoptosis may
ignificantly increase the life-span of infected T cells,
ossibly by playing a role in the pathogenesis of putative
TLV-2-associated disorders.
To clarify the mechanism of apoptosis inhibition
aused by HTLV-2, we analyzed the expression of the
essengers coding for some of the proteins belonging
o the Bcl-2 family that play a key role in controlling of the
poptotic pathway (recently reviewed by Adams and
ory, 1998). In particular, we considered the expression
f the genes coding for Bcl-2, Bcl-x, and Bax in Tax-2
ransfected or untransfected Jurkat cells and in the MoT
ell line. Bcl-2 is one of the best-known proteins provid-
ng protection against apoptosis. Of the two sets of
lternative spliced messengers produced by bcl-x, the
ong messenger (bcl-xL) codes for a protein that is ho-
mologous to Bcl-2 and protects cells from apoptosis,
whereas the short transcript (bcl-xS) produces a protein
lacking the aminoacid region of maximum identity with
Bcl-2 and can enhance cell sensitivity to apoptosis (Minn
et al., 1996). We also studied the expression of bax
RNA, which produces a protein of 21 kDa capable of
nhibiting both Bcl-2 and Bcl-xL by forming heterodimers
Adams and Cory, 1998).
PCR and Western blot analyses showed that the ex-
ression of Bcl-xL was higher in the transfected than in
the untransfected Jurkat cells; however, both had similar
titers of bcl-2, bax, and bcl-xS transcripts. Bcl-xL was also
overexpressed in MoT cell line.
The high bcl-xL/bcl-xS ratio observed in the transfected
ells (3:1) and the chronically HTLV-2-infected line (10:1)
uggest that HTLV-2 or Tax-2 can influence the splicing
rocess of bcl-x transcripts. It has been suggested that








































47FAS-MEDIATED APOPTOSIS IN HTLV-2 INFECTED T-CELL LINESapoptosis regulation (Aggarwal and Gupta, 1998): our
finding of an inversion of the bax/bcl-xL mRNA ratio in
urkat cells after transfection further supports the possi-
le role of Bcl-xL in protecting against Fas-mediated
apoptosis. Unlike Brauweiler et al. (1997), we did not find
any significant reduction in bax mRNA in the Jurkat cells
expressing Tax-2. Interestingly, Tsukahara et al. (1999)
have recently reported that HTLV-1 Tax protein can in-
duce resistance to apoptosis in a T-cell line after IL-2
deprivation by inducing the constitutive expression of
Bcl-xL through the NF-kB pathway. These data suggest
hat HTLV-1 and HTLV-2 Tax proteins may share similar
echanisms inducing apoptosis resistance in infected T
ells.
In conclusion, our findings indicate that HTLV-2 is
apable of inhibiting Fas-mediated apoptosis by means
f a mechanism involving tax-2 gene expression and an
ncrease in the intracellular concentration of bcl-xL
mRNA and protein. The pathogenic significance of this
observation deserves further investigation. Additional
studies are needed to evaluate whether the mechanism
affecting apoptosis may be different in other cell types as
is suggested by recent reports that WKAH rats infected
by HTLV-1 develop HAM/TSP and show increased oligo-
dendrocyte apoptosis in central and peripheral nervous
tissues (Ohya et al., 1997; Tomaro et al., 1996).
MATERIALS AND METHODS
Cell lines
HTLV-1-infected MT-2, HTLV-2-infected MoT and C19
(Gallo et al., 1991), and HTLV-free H9, Jurkat, CEM, and
Molt T-cell lines were cultured (0.5 3 106 cells/ml) in
RPMI 1640 supplemented with 2 mM of L-glutamine,
enicillin 50 units/ml, streptomycin 50 mg/ml, and 10%
fetal calf serum. The cell lines were kept at 37°C in 5%
CO2, and the culture medium was changed twice weekly.
ransfection
Permanent transfection of Jurkat cells was obtained
sing the entire coding sequence of HTLV-2 tax/rex con-
ained in the expression vector pBC 20.2 driven by the
MV promoter.
The expression vector was co-transfected in Jurkat
ells with the vector pCDNA III/AMP containing the neo-
ycin resistance gene by means of electroporation (260
and 960 mF). The cells (5 3 106) were suspended in
00 ml of RPMI complete medium and 10 mM HEPES
buffer before transfection. The transfected cells were
cultured and selected using G418 1 mg/ml in culture for
1 week and then cloned at 5 cells/well and kept under
selection with G418.
mCulture of Jurkat cells in HTLV-2-positive cell-free
supernatants
To study the transfer of Fas-mediated apoptosis resis-
tance, we treated Jurkat cells for 48 h with MoT super-
natant (untreated or inactivated at 56°C for 30 min)
(Copeland et al., 1994). HTLV-free supernatant from the
H9 cell line was used as control. Briefly, 1 3 106 cells
were incubated for 48 h with 1 ml of the supernatants at
37°C and then, after washing with PBS, analyzed for Fas
expression and apoptosis. The presence of viral genome
in the MoT supernatant was proved by means of RT-
nested PCR.
Phenotype characterization
The expression of surface membrane molecules was
determined by means of flow cytometric analysis using
CD4 FITC, CD8 PE, and CD3 PerCP monoclonal antibod-
ies (MoAbs) (Becton Dickinson, CA).
To determine Fas expression, an unconjugated MoAb
(clone CH-11) was used with a fluorescein-conjugated
secondary antibody. Briefly, 1 3 106 cells were washed in
PBS containing 1% FCS and 0.1% sodium azide, sus-
pended in 100 ml of PBS, stained with 2.5 mg of anti-Fas,
and incubated at 4°C for 30 min. The cells were then
washed and suspended in 100 ml of PBS, stained with
he secondary antibody, and incubated for 20 min at 4°C.
fter a second wash, the cells were fixed in 1% parafor-
aldehyde for 30 min before analysis.
Fluorescence intensity was measured using a Coulter
lite flow cytometry equipped with a 15-mW, 488-nm
ir-cooled argon laser.
as-mediated apoptosis assay
One million effector cells were incubated in culture
edium for 15 h at 37°C with or without an anti-Fas
oAb (clone CH-11). After a first set of experiments
esigned to optimize antibody concentration, we de-
ided to use 100 ng/ml as this gave the best results in
erms of apoptosis induction.
The cells were harvested in the presence of antibod-
es, washed in PBS supplemented with 1% FCS and 0.1%
odium azide, and suspended in the appropriate me-
ium. An anti-Fas monoclonal antibody (clone ZB4) that
locks the apoptosis induced by the CH-11 clone was
sed to control specificity.
Apoptosis was determined by evaluating DNA frag-
entation using in parallel Hoechst 33372 and the Tdt-
ediated dUTP nick end labeling (TUNEL) technique
Boehringer Mannheim, Mannheim, Germany). One mil-
ion cells were suspended in PBS, stained with 4 mg/ml
oechst 33372 (Calbiochem, CA), and incubated for 30
in at 37°C. The apoptotic cells were evaluated by
eans of fluorescence microscopy.



































































48 ZEHENDER ET AL.cells were fixed in 4% paraformaldehyde, permeabilized
in a solution of 0.1% Triton X-100 in 0.1% sodium citrate,
and incubated for 1 h at 37°C in 50 ml TUNEL mixture
ontaining TdT and fluorescein dUTP; an equal aliquot of
ells was incubated without TdT under the same condi-
ions. The cells were then washed and analyzed by
eans of flow cytometry. The results are expressed as
he mean values of at least three independent experi-
ents.
TLV nucleic acid detection and semiquantitation
The nucleic acids were purified using commercially
vailable extraction kits following the protocol suggested
y the manufacturer (High Pure PCR Template Prepara-
ion Kit and High Pure RNA Isolation Kit from Boehringer
annheim). In brief, 2 3 106 cells were suspended in
optimal lysis/binding buffers containing guanidine–HCl
and Triton X-100 and proteinase K (only for DNA extrac-
tion) in a Tris–HCl buffer. The nucleic acids were then
extracted by means of centrifugation through a glass
fiber fleece, and eluted using 50 ml of nuclease-free
sterile bidistilled water. The RNA-containing samples
were finally digested with DNAse I. HTLV-2 proviral DNA
and RNA levels were, respectively, determined by means
of nested-PCR and nested-RT–PCR using primers ampli-
fying a sequence included in the tax gene (sense outer
primer position at nucleotides 7219–7238, antisense po-
sition 7483–7464; sense inner primer position 7248–7267;
antisense position 7406–7386) as described elsewhere
(Zehender et al., 1998). The same primers were also
sed to detect HTLV-1 tax sequences (amplified region
358–7516).
To differentiate HTLV-1 and HTLV-2 proviruses, a com-
on HTLV-1/HTLV-2 sequence included in the pol gene
as amplified by means of single-stage PCR or RT–PCR
sing primers flanking the region between nucleotides
735 and 4920 and hybridized with specific HTLV-1 and
TLV-2 probes (position on HTLV-1 genome 4825–4850
nd HTLV-2 genome 4880–4898).
The absence of contamination was verified by using a
umber of negative controls (DNA extracted from known
TLV-free blood-donor PBMCs) and blank tubes (not
ontaining DNA) in each experiment.
To detect tax2/rex2 double-spliced mRNA, we devel-
ped a nested-RT–PCR using two pairs of primers am-
lifying a region containing the splice junction between
xons 2 and 3 coding for Tax-2 and Rex-2 proteins. The
uter and inner sense primers were located in exon 2
positions 5128–5149 and 5157–5178); the outer and inner
ntisense primers were located in exon 3 (nucleotides
483–7464 and 7406–7386). The PCR protocol involved
enaturation at 95°C for 30 s, annealing at 55°C for 30 s,
nd elongation at 72°C for 1 min for a total of 40 cycles.
he first and second steps were performed under the
ame conditions. The specificity of the amplified se-uences was evaluated by means of micro-plate hybrid-
zation with a probe recognizing HTLV-tax (pos. 7337–
376) (Zehender et al., 1997).
Semiquantitative PCR. The intracellular or supernatant
concentrations of HTLV DNA and RNA were evaluated by
means of limiting-dilution PCR, as previously described
(Zehender et al., 1998). Briefly, 2 mg of DNA or 5 ml of
DNA were serially diluted with each dilution being am-
lified by means of nested-PCR. The dilutions around the
nd point were retested in a five-replicate amplification
nd the concentration of nucleic acid calculated on the
asis of the equation C 5 2ln (N 0/N T), in which N 0 is
he number of negative results and N T is the number of
eplicate experiments involving a single dilution.
The titer of the tax sequences was expressed as PCR
nits (PU—the smallest amount of target sequence giv-
ng a PCR signal) and related to 103 cells or 1 ml of
upernatant. As previously described (Zehender et al.,
998), the correspondence between the number of cells
nd the amount of amplified DNA, and the presence of
ny PCR-inhibitory substances, was evaluated in each
ample by titrating a common sequence enclosed in the
eta-globin gene using primers PC04 and GH20 (respec-
ively, sense, pos. 273/254 and antisense, pos. 195/176).
correlation coefficient of 0.8 was observed between
he number of cells and the beta-globin titers (P , 0.01
by Spearman’s test).
The efficiency of the RNA extraction was controlled by
quantifying a ubiquitous messenger RNA coding for be-
ta-actin (sense primer, pos. 1196/1227; antisense primer,
pos. 1415/1384), which is constantly expressed in human
cells.
Evaluation of nested-PCR sensitivity and LD–PCR effi-
ciency. By amplifying different amounts of a plasmid
containing the entire proviral genome of HTLV-2 (pMo4,
kindly provided by Dr. G. Franchini of the National Can-
cer Institute, Bethesda, MD) dispersed in 1 mg of human-
HTLV-negative DNA, we observed a signal from about
one copy of target molecule. The efficiency of the limit-
ing-dilution–PCR protocol was evaluated by titrating
known amounts of pMo4 in 1 mg of human DNA. We
ound a correlation coefficient of 1 in a 5-log range
etween the titer and the number of amplified pMo4
opies (Zehender et al., 1998).
Detection and semiquantitation of bcl-2, bcl-x, bax
RNAs by limiting-dilution RT–PCR. Two micrograms
ntracellular total RNA obtained as already described
nderwent cDNA synthesis by means of Oligo-(dT) and
vian myeloblastosis virus (AMV) reverse transcriptase
t 42°C for 60 min. Serial 10-fold dilutions of the cDNA
ere then amplified using the following primers: for bcl-2
etection, sense primer 59-GGTGCCACCTGTGGTCCAC-
TG-39, antisense 59-CTTCACTTGTGGCCCAGATAGG-39
fragment length, 459 bp) (Bargou et al., 1996); for bax
detection, sense primer 59-ATGGACGGGTCCGGGGAG-





49FAS-MEDIATED APOPTOSIS IN HTLV-2 INFECTED T-CELL LINESCACAAAGAT-39 (fragment length 615, bp) (Martinez-Val-
dez et al., 1995). Bcl-xL and bcl-xS were simultaneously
mplified using sense primer 59-TTGGACAATGGACTG-
TTGA-39 and antisense 59-GTAGAGTGGATGGTCAGTG-
9, leading to amplification products of, respectively, 780
nd 591 bp (Bargou et al., 1996). The amplifications were
performed following the conditions suggested by Bargou
et al. (1996) and Martinez-Valdez et al. (1995).
The PCR products were revealed by means of
ethidium bromide staining after agarose electrophoresis.
Methods for the RNA titer calculation and expression has
been described above (see HTLV-LD–PCR).
The efficiency of RNA extraction was evaluated by
titrating in parallel the ubiquitous beta-actin mRNA in the
same samples (see above).
Immunoblot analysis
The cells were lysed in a buffer containing 0.15 M
NaCl, 50 mM Tris–HCl pH 8, 0.5% sodium deoxycholate
(DOC), 1% N-P40, 0.1% SDS and protease inhibitors
(Complete Protease Inhibitors Cocktail Tablets, Boehr-
inger Mannheim). The cell proteins were denatured by
means of the addition of an equal volume of sample
buffer 23 [100 mM Tris-base, pH 6.8, 4% sodium dodecyl
sulfate (SDS), 2% 2-mercaptoethanol, 20% glycerol and
0.2% bromophenol blue], heated for 5 min at 100°C
before separation by means of 10% SDS–polyacrylamide
gel electrophoresis (SDS–PAGE), and subsequently
transferred to a nitrocellulose membrane by means of
electroblotting. The membranes were blocked in 10%
non-fat dried milk, 20 mM Tris–HCl, pH 7.6, 137 mM NaCl,
and 0.1% Tween 20 (TBS-T) for 1 h at room temperature
and further incubated (overnight at 4°C) with the desired
primary antibody. Anti-Bcl-2, anti-Bcl-xL and anti-Bax an-
tibodies were diluted 1:5,000, and the membranes were
then incubated with the appropriate biotin-conjugated
secondary antibody (anti-rabbit, diluted 1:5,000). Anti-
body binding was visualised using a streptavidin horse-
radish peroxidase-conjugate diluted 1:10,000. The signal
was elicited by means of the ECL1 Plus Kit (Amersham
Pharmacia Biotech, England) according to the manufac-
turer’s instructions. Bands of reactivity were acquired
using Fluor-S MultiImager (Bio-Rad, CA), and densito-
metric analysis was performed by Multi-Analyst software
(Bio-Rad). The results of all of the experiments were
confirmed three times.
Bcl-2 protein expression was also determined by flow
cytometry. Briefly, the cells were fixed with ethanol 70%,
permeabilized with PBS containing 0.1% saponin, and
processed using a primary unconjugated anti-Bcl-2 an-
tibody at 20 mg/ml and a secondary FITC-conjugated
anti-mouse antibody.
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